The Latest

  • A sickle cell and normal blood cells are seen in red against a blue background in this colorized microscope image.
    Image attribution tooltip

    Janice Haney Carr/CDC/Sickle Cell Foundation of Georgia/AP

    Image attribution tooltip
    Deep Dive // Gene editing

    What if a CRISPR cure isn’t such an easy choice?

    A gene editing therapy developed by Vertex Pharmaceuticals and CRISPR Therapeutics can mute sickle cell disease’s most damaging symptoms. Yet treatment may not be as simple as its dramatic benefit makes it seem.

  • Smart industry concept. Automation and data exchange in manufacturing technologies.
    Image attribution tooltip

    shutterstock.com/DadBusiness

    Image attribution tooltip
    Sponsored by Target RWE

    Overcoming scalability challenges in real-world data processing for transformative patient care

    Accurate and timely processing of data is imperative to create robust analytical datasets that can be used in the RWE setting.

    FDA
  • A castor bean tick on a leaf
    Image attribution tooltip
    Erik Karits via Getty Images
    Image attribution tooltip

    Pfizer, after delay, completes enrollment in Lyme vaccine trial

    The announcement ends a lengthy setback that began when the company and partner Valneva accused a clinical trial site operator of study misconduct.

  • Lilly cancer drug cleared by FDA for expanded leukemia, lymphoma use

    Jaypirca, which has been on the market for less than a year, can now be used for more types of blood cancer but not as early as rival drugs from AbbVie and AstraZeneca.

    FDA
  • A closeup of an eye with light reflecting off of it.
    Image attribution tooltip
    Zorica Nastasic via Getty Images
    Image attribution tooltip

    EyePoint sees stock surge on AMD drug trial data

    The biotech said Phase 2 study results showed its experimental medicine for age-related macular degeneration was "non-inferior" to Regeneron's Eylea.

  • A computer screen shows the Pfizer logo and stock price at the New York Stock Exchange
    Image attribution tooltip
    Michael M. Santiago via Getty Images
    Image attribution tooltip

    Pfizer plans for oral obesity drug hit new setback

    The company won’t continue development of a twice-daily dose of its experimental weight loss medicine danuglipron after study data showed high rates of side effects.

  • An illustration for BioPharma Dive's deals database
    Image attribution tooltip
    Adeline Kon/BioPharma Dive
    Image attribution tooltip
    Deep Dive

    Biotech M&A is picking back up. Here are the latest deals.

    Roche’s deal for Carmot is the largest acquisition by value of an obesity drug developer this year, eclipsing smaller transactions for Versanis, Inversago Pharma and Embark Biotech.

    Updated Dec. 4, 2023
  • The European Union flag.
    Image attribution tooltip
    artJazz via Getty Images
    Image attribution tooltip
    Obesity drugs

    European regulators want to know more about the risks of GLP-1 drugs

    The EMA's safety committee has more questions for makers of the in-demand therapies as it reviews whether the drugs are linked to the risk of suicidal thoughts. 

  • A stylized stock chart is superimposed over a picture of U.S. dollars.
    Image attribution tooltip
    Maximusnd via Getty Images
    Image attribution tooltip

    Concentra, on the hunt for deals, bids for LianBio

    The Tang Capital-controlled company is bidding for LianBio shortly after making takeover offers for Rain Oncology and Theseus Pharmaceuticals.

  • An AbbVie sign is seen on the outside of a building in California.
    Image attribution tooltip
    Courtesy of AbbVie
    Image attribution tooltip

    AbbVie joins ADC dealmaking with $10B ImmunoGen buyout

    The acquisition of ImmunoGen gives AbbVie an approved medicine for ovarian cancer, and continues a pharma spending spree on antibody-drug conjugates.

  • Three people work in Empress Therapeutics' lab.
    Image attribution tooltip
    Permission granted by Empress Therapeutics
    Image attribution tooltip

    Flagship outlines plans to raise $3B for new fund

    The biotech company creator’s last fund, which closed in 2021, brought in $3.4 billion for investing in new drug startups.

  • A thumbnail illustration for BioPharma Dive's IPO tracker
    Image attribution tooltip
    Adeline Kon/BioPharma Dive
    Image attribution tooltip
    Deep Dive

    After a record run, fewer biotechs are going public. Here’s how they’re performing.

    Only three biotech IPOs have priced this quarter after an uptick in activity between July and September. A number of startups remain in queue, however.

    Updated Nov. 20, 2023
  • Abstract financial graph with up trend line on neon light colour background
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip

    CRO disputes Acelyrin’s implication of trial misconduct

    Trial contractor Fortrea is fighting back as Acelyrin unveils a CRO audit in the wake of a major late-stage study failure.

  • A sign showing Gilead's logo
    Image attribution tooltip
    Justin Sullivan via Getty Images
    Image attribution tooltip

    Gilead to lay off staff at cell therapy unit Kite

    The cuts will impact 7% of the cancer drug division’s employees, although about 90 new roles will be created around “areas of growth.”

  • Image attribution tooltip
    Jacob Bell
    Image attribution tooltip

    FDA names chief scientist Bumpus as Woodcock’s successor

    Bumpus, a former Johns Hopkins professor, named “creating a new model” for the FDA’s Office of Regulatory Affairs as one of her priorities when she steps into the role next year.

    FDA
  • Workers gather inside BioMarin’s gene therapy manufacturing plant in Novato, California.
    Image attribution tooltip
    Courtesy of BioMarin Pharmaceutical
    Image attribution tooltip

    BioMarin secures hemophilia gene therapy coverage in Germany

    Drawn-out negotiations led to a lower price than initially expected, but analysts called the agreement a step forward for the biotech company.

  • A horizontal headshot of Roivant Sciences chief executive officer Matt Gline.
    Image attribution tooltip
    Permission granted by Roivant Sciences
    Image attribution tooltip
    Q&A

    Roivant’s Matt Gline on raising capital and biotech’s outlook for 2024

    Fresh off a $7 billion deal with Roche, the chief executive spoke with BioPharma Dive about this year’s “discordant combination” of major biotech achievements and market headwinds.

  • Exterior sign of Bristol-Myers Squibb
    Image attribution tooltip
    Permission granted by Bristol-Myers Squibb
    Image attribution tooltip

    Bristol Myers pours $100M into RNA drugs for cardiovascular diseases

    Tuesday’s deal signals the pharmaceutical giant's confidence in Avidity Biosciences and its so-called antibody oligonucleotide conjugates.

  • An illustration of T cells attacking a cancer cell
    Image attribution tooltip
    Peddalanka Ramesh Babu via Getty Images
    Image attribution tooltip

    FDA investigating cancer risk linked to CAR-T cell therapy

    Reports of T cell malignancies following treatment triggered the FDA’s alert. But the event appears rare, according to companies and physicians.

    Updated Nov. 28, 2023
    FDA
  • Image attribution tooltip
    Novartis
    Image attribution tooltip

    Novartis sees brighter sales future as R&D revamp continues

    The pharma has overhauled its pipeline this year, cutting R&D programs outside of its four main therapeutic areas.

  • A office building is seen with a sign reading "GlaxoSmithKline."
    Image attribution tooltip
    Leon Neal via Getty Images
    Image attribution tooltip

    GSK cancer drug Blenrep gets surprise trial win

    One year after the U.K. drugmaker withdrew the multiple myeloma drug from the U.S. market because of negative data, new study results might crack open the door to a relaunch.

  • A photo of Sanofi headquarters in Paris, France.
    Image attribution tooltip
    Courtesy of Sanofi
    Image attribution tooltip

    Regeneron, Sanofi to seek new Dupixent approval in US after COPD success

    Results from the second of two Phase 3 trials testing the blockbuster drug in the respiratory condition showed treatment could reduce attacks and improve lung function. 

  • White flags bearing Novo Nordisk's logo are seen against a blue sky.
    Image attribution tooltip
    Courtesy of Novo Nordisk
    Image attribution tooltip

    Novo to expand French plant in GLP-1 production push

    The planned $2.3 billion investment follows an earlier $6 billion commitment to expand manufacturing for drugs like its in-demand medicine Wegovy.

  • A conceptual illustration of neural activity in a brain.
    Image attribution tooltip
    nopparit via Getty Images
    Image attribution tooltip

    Xenon drug misses main goal of depression study

    Yet, the company believes there were enough positive findings in the mid-stage trial to warrant further study of its drug, called XEN1101, in depression.

  • People walk past the Nasdaq MarketSite on October 12, 2022 in New York City.
    Image attribution tooltip
    Michael M. Santiago via Getty Images
    Image attribution tooltip

    Freeline, after cuts, agrees to take-private deal with Syncona

    The planned acquisition adds to a string of bargain buyouts and reverse mergers in the gene therapy field. 

  • Image attribution tooltip
    Spencer Platt via Getty Images
    Image attribution tooltip
    Emerging biotech

    Flagship-backed microbiome biotech Evelo to shut down

    The company said it had not found “a viable alternative” to closing down in the months since it hit a clinical setback and laid off staff.